Auxilium Pharmaceuticals Inc (AUXL)

AUXL (NASDAQ:Drugs)
$19.24
neg -0.36
-1.84%
Today's Range: 19.14 - 19.80 | AUXL Avg Daily Volume: 1,708,600
Last Update: 07/24/14 - 4:00 PM EDT
Volume: 510,399
YTD Performance: -5.45%
Open: $19.70
Previous Close: $19.60
52 Week Range: $16.36 - $32.89
Oustanding Shares: 50,259,206
Market Cap: 1,018,251,514
6-Month Chart
TheStreet Ratings Grade for AUXL
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 6 5 6
Moderate Buy 1 1 1 1
Hold 1 1 2 1
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.03 2.03 2.23 2.03
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -14.66
Price Earnings Comparisons:
AUXL Sector Avg. S&P 500
-14.66 0.00 28.87
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-28.80% 7.63% -2.39%
GROWTH 12 Mo 3 Yr CAGR
Revenue 1.40 0.90 0.23
Net Income -100.00 -0.65 0.00
EPS -100.00 -0.66 0.00
Earnings for AUXL:
EBITDA 0.01B
Revenue 0.40B
Average Earnings Estimates
Qtr (06/14) Qtr (09/14) FY (12/14) FY (12/15)
Average Estimate $-0.44 $0.02 $-0.59 $0.59
Number of Analysts 2 2 2 2
High Estimate $-0.36 $0.03 $-0.57 $0.74
Low Estimate $-0.53 $0.01 $-0.60 $0.43
Prior Year $0.22 $0.10 $0.31 $-0.59
Growth Rate (Year over Year) -302.27% -80.00% -288.71% 200.00%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

bullishAuxilium upgraded at MKM

May 28, 2014 | 7:37 AM EDT

AUXL was upgraded to Buy, MKM Partners said. $26 price target. Stock is down 30% since March, but Testim appears to have stabilized and Stendra is showing continued growth. 

bearishAuxilium Pharmaceuticals price target cut at UBS

Apr 30, 2014 | 7:35 AM EDT

AUXL lowered its number, UBS said. Full year guidance lowered  with shrinking T-gel shrinking and downward pressure on Rx in T-gel market. $31 price target and Buy rating. 

bearishAuxilium downgraded at Morgan Stanley

Mar 6, 2014 | 7:51 AM EST

AUXL was downgraded to Underweight, Morgan Stanley said. Valuation call, based on a $15 price target. 

bearishAuxilium downgraded at MKM

Jan 23, 2014 | 7:53 AM EST

AUXL was downgraded to Neutral, MKM Partners said. $23 price target. Valuation call, as the stock is up 25% over the past two weeks.

bullishAuxilium upgraded at Morgan Stanley

May 3, 2013 | 8:26 AM EDT

AUXL was upgraded from Underweight to Equal-weight, Morgan Stanley said. Risk/reward is more attractive, following a 50% decline since July. $14 price target. 

By

David Peltier

 | Nov 29, 2012 | 6:00 AM EST

Portfolio Mgr. David Peltier analyzes a volatile, low-dollar drug stock.

bearishAuxilium Pharma numbers lowered at Jefferies

Nov 8, 2012 | 8:22 AM EST

Shares of AUXL now seen reaching $29, Jefferies said. Estimates also lowered on Testim miss. Buy rating.

By

David Peltier

 | Aug 29, 2012 | 6:00 AM EDT

Portfolio David Peltier finds a pharma name that's quietly growing faster than its peers.

bullishAuxilium Pharma numbers raised at Jefferies

Aug 1, 2012 | 8:43 AM EDT

Shares of AUXL now seen reaching $32, Jefferies said. Estimates also raised on first quarter results. Buy rating.

bullishAuxilium Pharmaceutical numbers raised at UBS

Aug 1, 2012 | 8:38 AM EDT

Shares of AUXL now seen reaching $32, UBS said. Estimates also increased as Testim sales ramp should drive upside. Buy rating.

FB is trading $75.88, up 6.4% with IV30™ down 33.4%. This is a follow up to the post...
Bloomberg reporting around 2pm ET Zillow for Trulia...Z declined to comment, TRLA won't co...
With just over 40% of S&P 500 components having reported 2Q earnings, 158 of them or a...
DHI is the biggest loser in the S&P 500 today. The homebuilder is off over 10% on...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.